株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ファイコンパ(てんかん):予測と市場分析

Fycompa (Epilepsy) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 263612
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
ファイコンパ(てんかん):予測と市場分析 Fycompa (Epilepsy) - Forecast and Market Analysis to 2022
出版日: 2013年02月25日 ページ情報: 英文 51 Pages
概要

ファイコンパ(ペランパネル)は、エーザイが開発したAMPA受容体拮抗薬で、二次性全般化の有無にかかわらず、12歳以上のてんかん患者の部分発作に対する補助療法に用いられます。

当レポートでは、 ファイコンパ(ペランパネル)について調査分析し、てんかんの概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測、売上情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 発作の分類
  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • 生活の質(QOL)

第4章 疾病管理

  • 診断
  • 治療ガイドライン
  • 臨床診療

第5章 競合評価

  • 概要
  • 競合企業の戦略的評価

第6章 ファイコンパ(ペランパネル)

  • 概要
  • 治療の効果
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次
Product Code: GDHC1069DFR

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Fycompa (Epilepsy) - Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.

Fycompa (perampanel) is a first-in-class AMPA receptor antagonist indicated for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients with epilepsy ages 12 years and older. As an AMPA receptor antagonist, perampanel selectively targets the transmission of seizures by blocking the effects of glutamate. This MOA, which is different from that of the currently available AEDs, means that perampanel is the first approved AED in this new class of treatment. Perampanel is being developed by Eisai and was recently approved for marketing in Europe and in the US, and it is in the Phase III stage of development in Japan. Eisai established itself in the epilepsy market by bringing to market several other AEDs, including Zonegran, Banzel/Inovelon, and Zebinix. The company can leverage this market presence to promote perampanel.

Scope

  • Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Fycompa including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Fycompa for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Fycompa performance
  • Obtain sales forecast for Fycompa from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Classification of Seizures
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
    • 3.2.3. Prognosis
    • 3.2.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Treatment Guidelines
  • 4.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Fycompa (perampanel)

  • 6.1. Overview
  • 6.2. Therapeutic Role
  • 6.3. Efficacy
  • 6.4. Safety
  • 6.5. SWOT Analysis
  • 6.6. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Prevalent Epilepsy Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Authors
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Contact Us
  • 7.10. Disclaimer

List of Tables

  • Table 1: Epilepsy Syndromes by Age at Onset (2009 ILAE Classification)
  • Table 2: Classification of Seizures
  • Table 3: Etiology of Epilepsy According to Age
  • Table 4: Etiology of Partial Seizures
  • Table 5: Etiology of Generalized Seizures
  • Table 6: Some of the Genes Involved in Epilepsy
  • Table 7: Summary of Diagnostic Tools for Epilepsy
  • Table 8: Treatment Guidelines for Epilepsy
  • Table 9: AED Options by Seizure Type
  • Table 10: Top Three AEDs Prescribed for Epilepsy by Market
  • Table 11: Types of Epilepsy Surgery
  • Table 12: Leading Treatments for Epilepsy, 2012
  • Table 13: Product Profile - Fycompa
  • Table 14: Fycompa SWOT Analysis, 2012
  • Table 15: Global Sales Forecasts ($m) for Fycompa (perampanel), 2012-2022
  • Table 16: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation
  • Figure 2: Mechanisms of Action of AEDs at the Synapse
  • Figure 3: AED Selection Based on Comorbidity
Back to Top